ONWARD Medical has successfully raised EUR 40.6 million through an accelerated bookbuild offering, with a notable EUR 25 million investment from EQT Life Sciences, extending its cash runway until the first quarter of 2028. The funds will support the development of its neurotechnology therapies, particularly the ARC-IM implantable system, and expand the commercial rollout of the ARC-EX system in the U.S. and Europe. The company focuses on restoring movement in individuals with spinal cord injuries and is innovating through integrated technologies like brain-computer interfaces and AI.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://ggba.swiss/en/onward-medical-raises-eur-40-million-to-extend-arc-therapy-commercialization/
